{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:46:28Z","timestamp":1783788388470,"version":"3.55.0"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The aim of this review is to summarize the current knowledge of low-dose methadone treatment in palliative cancer care. In Sweden, methadone is quite common in specialized palliative care, where almost a tenth of patients are prescribed this drug. Negative attitudes towards methadone do not seem to prevent it from being used for pain management, and by starting with low doses and then increasing slowly and gradually, methadone can apparently be introduced safely. It is still uncertain whether methadone has a better analgesic effect than other opioids. However, for pain relief in cancer patients with severe and complex cancer-related pain, NMDA receptor inhibition with methadone may, in selected cases, be an attractive alternative, especially in the form of low-dose supplements to other ongoing opioids. Due to long half-life and complex metabolism, the use of methadone requires an experienced physician and solid follow-up. Continuous administration of opioids, including low-dose methadone, has been proven effective and safe in reducing pain in dying patients without increasing the risk of confusion, regardless of age.<\/jats:p>","DOI":"10.3390\/life12050679","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T08:26:35Z","timestamp":1651566395000},"page":"679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Use of Low-Dose Methadone as Add-On to Ongoing Opioid Treatment in Palliative Cancer Care\u2014An Underrated Treatment?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-833X","authenticated-orcid":false,"given":"Per","family":"F\u00fcrst","sequence":"first","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden"},{"name":"Palliative Medicine, Stockholms Sjukhem Foundation, SE-112 19 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis","volume":"51","author":"Hochstenbach","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","article-title":"Treatment of cancer pain","volume":"377","author":"Portenoy","year":"2011","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.2014.56.0383","article-title":"Quality of cancer pain management: An update of a systematic review of undertreatment of patients with cancer","volume":"32","author":"Greco","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/jpm.2019.0243","article-title":"Factors Associated with Improvement in Uncontrolled Cancer Pain without Increasing the Opioid Daily Dose among Patients Seen by an Inpatient Palliative Care Team","volume":"23","author":"Qian","year":"2020","journal-title":"J. Palliat. Med."},{"key":"ref_6","first-page":"Cd012592","article-title":"Opioids for cancer pain-an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","unstructured":"Region_Stockholms_L\u00e4kemedelskommitte (2020, October 22). Kloka Listan Sm\u00e4rta och Inflammation. Available online: http:\/\/klokalistan2.janusinfo.se\/20201\/Smarta-inflammation\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90025-9","article-title":"The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions","volume":"43","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/0269216312464408","article-title":"Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study","volume":"27","author":"Rayment","year":"2013","journal-title":"Palliat. Med."},{"key":"ref_11","unstructured":"Fitzgibbon D, L.J. (2010). The Perception of Pain. Cancer Pain Assessment, Diagnosis and Management, Wolters Kluver\/Lippincott Williams & Wilkins."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pain.2008.04.025","article-title":"The Kyoto protocol of IASP Basic Pain Terminology","volume":"137","author":"Loeser","year":"2008","journal-title":"Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: Implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"ref_14","unstructured":"(2022, April 26). International Association for the Study of Pain: IASP Terminology. Available online: www.iasp-pain.org."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.phrs.2009.04.002","article-title":"Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain","volume":"60","author":"Sotgiu","year":"2009","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.gastro.2003.11.047","article-title":"The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor","volume":"126","author":"Willert","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2049463714545136","article-title":"Cancer pain physiology","volume":"8","author":"Falk","year":"2014","journal-title":"Br. J. Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(97)13391-2","article-title":"The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord","volume":"223","author":"Gorman","year":"1997","journal-title":"Neurosci. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3940(95)11364-3","article-title":"Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord","volume":"187","author":"Ebert","year":"1995","journal-title":"Neurosci. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s005200000180","article-title":"Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration","volume":"9","author":"Davis","year":"2001","journal-title":"Support Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2021.05.014","article-title":"Methadone Does Not Block NMDA Receptors","volume":"62","author":"Davis","year":"2021","journal-title":"J. Pain Symptom Manag."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","article-title":"Pharmacokinetics of methadone","volume":"19","author":"Lugo","year":"2005","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.4103\/IJPC.IJPC_180_17","article-title":"Practical Pharmacology of Methadone: A Long-acting Opioid","volume":"24","author":"Sunilkumar","year":"2018","journal-title":"Indian J. Palliat. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1089\/jpm.2017.0090","article-title":"Clinical Outcomes of Start-Low, Go-Slow Methadone Initiation for Cancer-Related Pain: What\u2019s the Hurry?","volume":"20","author":"Hawley","year":"2017","journal-title":"J. Palliat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jpainsymman.2017.10.017","article-title":"Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review","volume":"55","author":"Mercadante","year":"2018","journal-title":"J. Pain Symptom Manag."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1742-1241.2008.01990.x","article-title":"The role of methadone in cancer pain treatment\u2014A review","volume":"63","author":"Leppert","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"ref_27","first-page":"CD003971","article-title":"Methadone for cancer pain","volume":"2","author":"Nicholson","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/15360288.2014.938883","article-title":"Therapeutic challenges in cancer pain management: A systematic review of methadone","volume":"28","author":"Good","year":"2014","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2004.03.172","article-title":"Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study","volume":"22","author":"Bruera","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jpainsymman.2016.05.022","article-title":"Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain)","volume":"52","author":"Poulain","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.ejca.2011.06.047","article-title":"How to switch from morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II trial","volume":"47","author":"Moksnes","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2016.06.025","article-title":"Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer","volume":"65","author":"Haumann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1200\/JCO.1998.16.11.3656","article-title":"Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home","volume":"16","author":"Mercadante","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/oncolo\/oyab081","article-title":"Methadone as First-line Opioid for the Management of Cancer Pain","volume":"27","author":"Mercadante","year":"2022","journal-title":"The Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1191\/0269216303pm815oa","article-title":"Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial","volume":"17","author":"Morley","year":"2003","journal-title":"Palliat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"McNicol, E.D., Ferguson, M.C., and Schumann, R. (2022, April 26). Methadone for Neuropathic Pain in Adults. Cochrane Database Syst. Rev., Available online: https:\/\/doi.org\/10.1002\/14651858.CD012499.pub2.","DOI":"10.1002\/14651858.CD012499.pub2"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fawoubo, A., Perceau-Chambard, \u00c9., Ruer, M., Filbet, M., Tricou, C., and Economos, G. (2021). Methadone and neuropathic cancer pain subcomponents: A prospective cohort pilot study. BMJ Support. Palliat. Care.","DOI":"10.1136\/bmjspcare-2021-003220"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00520-004-0650-1","article-title":"Addition of a second opioid may improve opioid response in cancer pain: Preliminary data","volume":"12","author":"Mercadante","year":"2004","journal-title":"Support Care Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2011.06.005","article-title":"Use of methadone as a coanalgesic","volume":"42","author":"McKenna","year":"2011","journal-title":"J. Pain Symptom Manag."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2011.12.270","article-title":"Use of methadone as a coanalgesic: Response to McKenna and Nicholson","volume":"43","author":"Haughey","year":"2012","journal-title":"J. Pain Symptom Manag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/jpm.2012.0335","article-title":"Addition of methadone to another opioid in the management of moderate to severe cancer pain: A case series","volume":"16","author":"Wallace","year":"2013","journal-title":"J. Palliat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/jpm.2015.0525","article-title":"Methadone as a Coanalgesic for Palliative Care Cancer Patients","volume":"19","author":"Courtemanche","year":"2016","journal-title":"J. Palliat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/pmr.2020.0034","article-title":"Galloway L Ultralow-dose adjunctive methadone with slow titration, considering long half-life, for outpatients with cancer-related pain","volume":"1","year":"2020","journal-title":"Palliat. Med. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/AJP.0000000000000959","article-title":"A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain","volume":"37","author":"Duarte","year":"2021","journal-title":"Clin. J. Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/jpm.2017.0157","article-title":"Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment","volume":"21","author":"Furst","year":"2018","journal-title":"J. Palliat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/jpm.2019.0253","article-title":"The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care","volume":"23","author":"Furst","year":"2020","journal-title":"J. Palliat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Furst, P., Lundstrom, S., and Strang, P. (2020). Methadone in Swedish specialized palliative care-Is it the magic bullet in complex cancer-related pain?. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230845"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"F\u00fcrst, P., Lundstr\u00f6m, S., Klepstad, P., and Strang, P. (2020). Continuous subcutaneous infusion for pain control in dying patients: Experiences from a tertiary palliative care center. BMC Palliat. Care, 19.","DOI":"10.1186\/s12904-020-00681-3"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0304-3959(92)90266-E","article-title":"The NMDA-receptor antagonist CPP abolishes neurogenic \u2019wind-up pain\u2019 after intrathecal administration in humans","volume":"51","author":"Kristensen","year":"1992","journal-title":"Pain"},{"key":"ref_50","first-page":"5798285","article-title":"A Review of Nonanesthetic Uses of Ketamine","volume":"2020","author":"Pribish","year":"2020","journal-title":"Anesthesiol. Res. Pract."},{"key":"ref_51","first-page":"Cd003351","article-title":"Ketamine as an adjuvant to opioids for cancer pain","volume":"6","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2012.42.1081","article-title":"Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain","volume":"30","author":"Hardy","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/mol.117.111427","article-title":"Properties of Triheteromeric N-Methyl-d-Aspartate Receptors Containing Two Distinct GluN1 Isoforms","volume":"93","author":"Yi","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1021\/acschemneuro.7b00117","article-title":"Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites","volume":"8","author":"Maolanon","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11916-017-0607-y","article-title":"Multimodal Analgesia, Current Concepts, and Acute Pain Considerations","volume":"21","author":"Helander","year":"2017","journal-title":"Curr. Pain Headache Rep."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/5\/679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:36Z","timestamp":1760137536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/5\/679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["life12050679"],"URL":"https:\/\/doi.org\/10.3390\/life12050679","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}